<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">At this point in time, there are no high-quality data available to support successful treatment strategies for COVID-19 in children. Most publications have commented on a variety of supportive treatments including antipyretics, oxygen therapy and antibiotics for secondary bacterial infections [
 <xref rid="bib26" ref-type="bibr">26</xref>]. Clinical trials are also being conducted globally, with the intention of discovering effective and safe treatments. Over the last few weeks, two investigational drugs: Remdesivir and Hydroxychloroquine were granted an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA)[
 <xref rid="bib28" ref-type="bibr">28</xref>,
 <xref rid="bib29" ref-type="bibr">29</xref>] for the treatment of suspected or laboratory-confirmed COVID-19 cases based on clinical trials showing that these investigational drugs can shorten the time to clinical recovery in some patients [
 <xref rid="bib30" ref-type="bibr">[30]</xref>, 
 <xref rid="bib31" ref-type="bibr">[31]</xref>, 
 <xref rid="bib32" ref-type="bibr">[32]</xref>, 
 <xref rid="bib33" ref-type="bibr">[33]</xref>]. The FDAâ€™s authorization of Remdesivir has been extended to include hospitalized children with severe COVID-19 symptoms (patients requiring supplemental or mechanical ventilation) [
 <xref rid="bib29" ref-type="bibr">29</xref>].
</p>
